Validation of a biomarker set for the identification of patients at risk for developing POD/POCD.

Validation of a biomarker set for the identification of sub-types of patients with POD/POCD (patient stratification).

Insights into structural brain changes associated with POD/POCD using structural neuroimaging biomarkers.

Insights into the pathophysiology of POD/POCD using functional neuroimaging biomarkers.

Insights into the molecular mechanisms (cholinergic anti-inflammatory pathway) associated with the development of POD/POCD.

Insights into the molecular mechanisms (neurometabolic pathway) behind the development of POD/POCD.

Insights into the molecular relationship between POD/POCD and risk for AD- possibly discovering new molecular risk mechanisms for developing AD.

Insights into the relationship between POD/POCD and risk for AD with regard to structural and functional brain changes.

Health-economic data (HTA) for the cost/benefit ratio of biomarker-driven personalized decision-making in drug trials and clinical care of patients at risk of / suffering from POD/POCD patients.